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Tuberculosis disease continues to contribute to the mortality burden globally. Due to
the several shortcomings of the available diagnostic methods, tuberculosis disease
continues to spread. The difficulty to obtain sputum among the very ill patients and
the children also affects the quick diagnosis of tuberculosis disease. These challenges
warrant investigating different sample types that can provide results in a short time.
Highlighted in this review are the approved pulmonary tuberculosis diagnostic methods
and ongoing research to improve its diagnosis. We used the PRISMA guidelines for
systematic reviews to search for studies that met the selection criteria for this review. In
this review we found out that enormous biosignature research is ongoing to identify host
biomarkers that can be used as predictors of active PTB disease. On top of this, more
research was also being done to improve already existing diagnostic tests. Host markers
required more optimization for use in different settings given their varying sensitivity and
specificity in PTB endemic and non-endemic settings.
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INTRODUCTION
Tuberculosis Burden and Eradication Strategies
Tuberculosis (TB) continues to infect many people worldwide causing at least 1.2 million deaths
annually. Reducing new infections and mortality among patients who are difficult to diagnose with
the currently available methods is paramount (1). Improved, timely and cost-effective diagnosis of
active TB disease is a key strategy for ending the TB epidermic.
The World Health Organization (WHO) implemented strategies to end TB since 1995 to date
(2, 3) focused on the sustainable development goal 3, 3.3 whose main objective is to end pandemics
like TB by 2030. The SDG 3.3.2 aims at reducing TB incidence in the population (4). Achieving all
these strategies is highly dependent on the widespread diagnosis of pulmonary TB cases within the
population (5).
Given that immune response against TB is a continuum, predicting those who are progressing
from “latent tuberculosis infection (LTBI)” to active TB disease is as important in the diagnosis of
TB disease among those who may require preventive therapy (6) including the HIV co-infected
subjects. While tests such as “Interferon-gamma release assays (IGRAs)” can indicate that an
individual was exposed to Mtb, owing to T cell reactivity to TB antigens, these have not shown
good results in diagnosing active pulmonary TB disease. Antibody tests on the other hand are not
approved for TB diagnosis by WHO due to their poor sensitivity and specificity (4).
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Current diagnostic methods have limitations like long
turnaround time, low sensitivity, cost, inability to distinguish
active TB disease from latent infection, high infrastructure, and
training needs among others (7). Molecular diagnostic tests are
currently providing a rapid TB diagnostic platform providing
results within 2 h thereby improving patient care (8). Currently,
the Gene Xpert test is widely distributed in resource-limited
settings for TB disease screening in high TB endemic settings (9).
Although we have good tests for tuberculosis, high TB
incidence could still be attributed to challenges with the available
diagnostic tests as well as the inability to diagnose TB disease
early. The very young (10), the elderly who present as pneumonia
and HIV infected persons on antibiotics usually present with
paucibacillary TB, negative smear thusmissed diagnosis (11). The
delay in seeking health services as well as poor health services
delivery also contributes to an increase in TB incidence. In
resource-limited settings, several factors contribute to high TB
incidence. These include, the delay in seeking health services
and long turnaround time (TAT) for reading smear slides given
TABLE 1 | Currently approved tuberculosis diagnostics.
Diagnostic method Advantages Limitations
Chest radiography - Can be used as an initial screening tool - Costly
- Not widely accessible
- test accuracy may be affected by variation between readers.
Direct microscopic examination*:
identifies acid-fast bacilli through the




- Unable to discriminate between mycobacterial species,
- Time-consuming for lab technicians,
- Depends on sputum sample quality and bacterial load,
- Cannot detect drug resistance
- Cannot differentiate live or dead bacilli
Fluorescence light-emitting diode
microscopy: Identifies acid-fast bacilli





- Needs well-trained technicians,
- Poor performance among the HIV positive who are paucibacillary,
- Depends on the quality and bacterial load of the sputum specimen
- Cannot detect drug resistance
- Cannot differentiate live or dead bacilli
Culture (liquid): Identifies Mtb with
radio-active and fluorometric growth
indicators (MGIT),
- High sensitivity
- Permits testing for drug resistance.
- Expensive,
- Needs well-trained technicians,
- Needs established infrastructure like Biosafety facilities
Culture (Solid): Identifies Mtb growth
on solid (LJ and Middlebrook) media
- Permits testing for drug resistance. - Long turnaround time,
- Low sensitivity
- Expensive,
- Needs well-trained technicians,
- Needs established infrastructure like Biosafety facilities
Xpert MTB/RIF*: detect Mtb complex
DNA and mutations associated with
rifampicin resistance
- High sensitivity,
- Permits testing for rifampicin resistance,
- Low turn around time (2 h)
- High cost for procuring the machine and consumables like cartridges
- Needs well-trained technicians,
- Cannot differentiate live or dead bacilli
- Has stringent operational requirements like uninterrupted power supply,
temperature below 30◦C, adequate storage for cartridges at temperatures
below 28◦C
- Has programmatic requirements like software and annual calibration,
- Waste disposal for cartridges is a concern
TB LAM*: Detects lipopolysaccharide
which is shed from mycobacterial cell
walls in urine.
- Easy to collect and store,
- Does not require high biosafety requirements.
- Has improved sensitivity among HIV positive
- Applicable primarily among HIV/AIDs patients
- Sub-optimal sensitivity
Xpert MTB RIF, GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA); LAM, lipoarabinomannan; MGIT, Mycobacterium growth indicator tube; LJ, Löwenstein-Jensen.
*Applies to resource-limited settings, which often have the highest TB burdens.
the high workload in the health centers (12). There is a drive
to enhance research using readily available samples to identify
bio-signatures that can diagnose active TB disease.
In many endemic and often resource-limited settings, the
diagnosis of active TB disease is a challenge despite the important
advances in the development of new diagnostic tools. For
this reason, a simple, sensitive, and rapid diagnostic point of
care (POC) test may be required for screening of individuals
presumed to have active TB in high TB endemic settings asmaybe
offered by immunological tests. These can then be followed
by confirmatory tests as required. To date, despite all research
efforts, none of the immunologically based TB disease detection
tests is WHO approved (13).
In this review, we highlight the approved diagnostic methods
(Table 1) for TB and discuss attempts made to identify blood-
based diagnostic approaches and other potential samples which
may lead to a point of care test for TB. Also highlighted are other
diseases that may affect pulmonary tuberculosis disease diagnosis
and progression.
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RESEARCH QUESTION AND AIMS
What are the past and present approaches to diagnosis of active
pulmonary tuberculosis?
Objectives
1. To highlight the currently approved active PTB
diagnostic methods.
2. To describe the advances in blood biomarkers for diagnosis of
TB disease in children and adults regardless of HIV status.
3. To describe the performance of Mtb derived markers for
predicting active PTB disease in HIV-negative adolescents
and adults.
Methods
This review was done using the Preferred Reporting Items
for Systematic Review and Meta-Analysis Protocols (PRISMA)
checklist. A thorough literature search for studies that meet the
inclusion criteria was done and the relevant data extracted. The
study was conducted and completed between March 2020 and
January 2021.
Inclusion Criteria
The following studies were included in this review: cross-
sectional, cohort, case–control, and randomized control studies
involving active PTB subjects regardless of HIV status. Also,
studies using host blood biomarker signatures to predict active
PTB disease with a microbiological reference standard of either
Mtb culture and/or XpertMTB/RIF or smear microscopy, studies
using either TST or IGRA for predicting active PTB disease. In
addition, studies comparing TB disease cases to controls with or
without other diseases, and with or without latent Mtb infection
plus pediatric and adults PTB studies. Studies published both as
abstracts and full articles between January 1995 to January 2021
published in English regardless of location or country of origin
were also included.
Exclusion
We excluded PTB treatment and latentlyMtb-infected biomarker
studies, conducted in animals; did not report sensitivity and
specificity, and where authors did not respond to enquiries
for data within 4 weeks of inquiry. Unpublished reports and
conference proceedings were excluded due to absence of peer
review and difficulty in obtaining data.
Literature Search
The searches were conducted in Medline through PubMed
and Google scholar databases. The search Key terms used
included: Tuberculosis, Mtb, diagnosis, diagnostics, detect,
predict, blood, immune markers, immunodiagnostic markers,
host, TB human biomarker, TB diagnostic bio-signature,
transcriptome, transcriptomic, Mtb RNA, accuracy, diagnostic
accuracy, performance, sensitivity and specificity, area under the
curve (AUC), receiver operating characteristic (ROC) curves.
Any other citations from identified literature that were not
originally identified during the search were also included.
Study Selection
ARN searched the databases for all studies that met the selection
criteria by title, abstract and later by full text. The selected studies
were further screened by two reviewers (HMK and NC) for their
quality as to whether they were fit for inclusion in this review.
Articles were categorized as (i) included, (ii) not included, or
(iii) pending reviewer discretion. The two reviewers conferred to
resolve any disagreements about pending publications, and if a
consensus could not be reached, a third reviewer (ARN) acted as
the tiebreaker.
Data Extraction and Management
Data was extracted from the relevant articles into a Microsoft
word file which was shared among the reviewers to facilitate
online sharing and screening of data between reviewers. For each
study, we extracted the reported performance data; the diagnostic




The currently approved methods for TB diagnosis are listed in
Table 1 below with their limitations.
Sputum Exam
There are several currently approved methods for TB diagnosis
and these are either microbiological or molecular methods
that detect the pathogen itself or its products. Sputum smear
microscopy and culture still present limitations such as low
sensitivity (15). Microscopy has been advanced with fluorescence
light-emitting diode which provides better sensitivity (6,
16). Sputum culture although more sensitive than sputum
microscopy presents challenges of long TAT, high cost plus high
infrastructure and training needs (17). Among those who show
up in the TB clinic to be screened, delayed diagnosis of active
pulmonary TB contributes to increased PTB disease burden
and spread of the infection (18). All sputum-based diagnostic
methods have limited use among children and the very sick who
are unable to cough.
GeneXpert
Currently, the Xpert© MTB/RIF assay (Cepheid Inc, Sunnyvale,
Calif., USA) is what comes close to a rapid molecular diagnostic
tuberculosis test although it is dependent on good quality
sputum sample (19). Tuberculosis diagnosis can also be through
the detection of host biomarkers or pathogen biomarkers
such as Mycobacterium tuberculosis (Mtb) products (20). These
challenges lead to delayed diagnosis of active pulmonary TB
thereby contributing to increased PTB disease burden and spread
of infection.
Chest Imaging
Chest radiography (x-ray) has the potential as an initial screening
test for active pulmonary TB. Imaging advances include Positron
emission tomography (PET) scans which are showing potential
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FIGURE 1 | PRISMA flow chart indicating the data extraction process. Adapted from Page et al. (14).
for identifying active TB lesions. 2-[18F]fluoro-2-deoxyglucose
(18F-FDG) PET/CT scans have shown potential for detecting
active pulmonary TB lesions (21) and treatment response (22).
In cases where sputum is not available e.g., in children,
attempts are made to collect other specimens e.g., gastric washes.
The collection of these specimens is not always practical in
Frontiers in Medicine | www.frontiersin.org 4 September 2021 | Volume 8 | Article 709793
Namuganga et al. Past and Present Approaches to Diagnosis of Active Pulmonary Tuberculosis
resource-limited settings, which often do not have highly skilled
health care workers. These and other specimens are collected
from extra pulmonary TB patients (EPTB) for TB diagnosis
but the yield of the microbiological tests is still low due
to the paucibacillary nature of these specimens compared to
sputum (23).
For this reason, blood-based diagnostic methods remain
paramount for quick tuberculosis point of care tests.
Immunodiagnostic Tests for Tuberculosis
Promising Blood-Based Diagnostic Approaches
Under Research and Development
Tests making use of the immune responses to tuberculosis
would be a valid addition to current tests to improve active
tuberculosis diagnosis. Some immunological test formats will
have the possibility of minimal invasiveness, minimal training
requirements, simplicity, and low cost and will easily serve as
POC tests for rapid diagnosis of tuberculosis (24). Some of
these tests are available as immune-chromatographic methods as
lateral flow strips and as “enzyme-linked immunosorbent assay
(ELISA)” (25).
The absence of validated active TB predictive biomarkers
hinders their use as immune-based active TB disease diagnostic
methods. This coupled with the inability to differentiate disease
states warrants continued research. Ideally, the most appropriate
cytokine panel for studying PTB disease is one that covers
the whole spectrum of TB infection and disease (26) which
includes may include “T helper 1 and 2 (Th1/Th2)” balance,
granuloma formation, macrophage activation, T-cell stimulation
and limitation of inflammation (27). In this review, the following
blood-based avenues have been discussed: LTBI blood-based tests
as predictors of active TB disease, antibodies, cytokines, blood
transcriptomic signatures, and immune metabolic markers.
Humoral Response
Antibody Tests for Active Tuberculosis
Antibodies to active TB have previously been used as both
therapeutic (28) and diagnostic agents of TB (29–31). Antibody
levels have shown potential as predictors of high bacterial
load and active TB disease progression among the LTBI (32).
In-vitro immunodiagnostic studies utilize Mtb antigens in
single or multiple combinations to evaluate the production of
“immunoglobulin (Ig)” A, G, and M antibodies in blood samples
(33, 34). These are incorporated onto lateral flow strips that are
easy to read on lateral flow readers (35). Serological tests that
have been developed for the market so far (Table 2) include the
Anda TB test, IBL test, Pathozyme-Myco IgG test (Myco G),
and TB complex test (36). While these approaches have yielded
promising results, there are no approved tests in the market yet
due to their poor sensitivity and specificity ranging between 57
and 94% (37, 38).
Other Mtb antigens that have been used include BCG, PPD
(39, 40), LAM, TB15.3, TB51A, CFP10-ESAT6-A, CFP, CW (41,
42). Titers for IgG were higher in active TB disease compared
with LTBI or controls in children (40) and adults (39, 41, 42).
Higher IgG titers also correlated with reduced T cell counts and
disease progression as was seen in TB/HIV) (42, 43).










IBL IgG 76 57 recombinant
proteins 18, 36, and
40 kDa
Myco G IgG 50 94 Lipoarabinomannan
& Rv0934
Anda TB IgG 78 79 Antigen 60
TB complex
test
IgG 52 93 Rv0934 & Rv2031c
A study done in South Africa investigated the serodiagnostic
reactivity of periplasmic phosphate-binding lipoprotein
PstS3 (Rv0928), L-alanine dehydrogenase (AlaDH) (Rv2780),
nitrate/nitrite response transcriptional regulator NarL (Rv0844c),
19 kDa lipoprotein antigen pre- cursor LpqH (Rv3763), and
lipoprotein MPT83 (Rv2873) evaluated IgG and IgA antibody
production. High IgA levels but not IgG were observed among
the LTBI group and were predictive of progression to active TB
disease in this group (32). In another study from the same group
that assessed IgA and G levels among slow and fast responders
to TB treatment, slow responders had higher IgA and IgG levels
compared to fast responders. IgG levels dropped significantly
following TB treatment (44).
Despite being an attractive point of care test for active
pulmonary tuberculosis, antibody tests for PTB have not been
approved for use globally due to their inaccuracy, inconsistency,
and poor specificity (13). This inaccuracy can be due to many
factors including cross-reactivity (45), age, and the inability to
differentiate recent antibodies from already existing ones. In high
TB endemic areas, high background antibody concentrations
among controls hinder the prognostic potential of antibodies
among these populations. Given that all pathogens generate an
antibody response, it is difficult to identify whether antibodies
are toward a recent or a previously established active PTB disease
in vivo.
Due to the unsatisfactory performance of sero-diagnostics,
assays utilizingMtb-specific antibodies (45) in biological samples
like serum are available on the market but are not approved by
WHO or “Food and drug authority (FDA).” In-depth studies
need to be done to assess Mtb humoral response as well as
the inability of antibodies to confer protective immunity to
tuberculosis (46).
Cell-Mediated Immune Response to Tuberculosis
TST and IGRA for Active TB Diagnosis
The “tuberculin skin test (TST)” and “interferon-gamma release
assays (IGRA)” are used globally to determine exposure to
Mtb but are not ideal for predicting recent infection or active
Tb disease, especially in high TB endemic areas. Although
relatively old, the TST detects Mtb and Mtb-related purified
protein derivatives owing to its low specificity as it contains a
crude mixture of antigens, which are also available in “non-
tuberculous mycobacterium NTMs.” Because TST has low
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sensitivity and specificity, the (IGRA) has been introduced to
determine exposure to Mtb but not as a replacement for the
TST. In the developed world, the IGRA is used as supplementary
tests to TST for improved performance given the age dependant
production of interferon-gamma, especially among pediatrics.
Given that multiple cytokines and chemokines contribute to the
immune response to the bacilli, a biomarker signature rather than
a single cytokine or chemokine is required to predict active TB
disease and infection (47).
A signature comprising, IL1ra, IFNg, MIP-1b, and TGF could
predict active TB disease better in QuantiFERON (QFT) gold-
in-tube supernatants (48). Another study evaluating additional
markers in (QFT) gold plus supernatants (49) showed differential
expression of GM-CSF, IL-33, ITAC-1, I-309, MIG, ADAMTS13,
IL-1 α, IL-22, IL-2, IL-3, and TGF-α among those with active
TB disease. Recently, efforts focused on the discovery of ex
vivo biomarkers are taking lead as these may be more easily
converted to point of care (POC) tests. Given the huge amount of
research in this area, it is paramount to translate the researched
signatures to POC tests. Studies have been done to evaluate
the potential of TST and IGRA for active PTB diagnosis but
these do not have the predictive potential for active PTB
diagnosis (50, 51).
TB-Specific Antigen to Phytohaemagglutinin Ratio for Active
PTB Diagnosis
The T-SPOT assay that analyses IFNg producing T Spot-forming
cells (sfc) isolated from PBMCs for their response to TB antigens
(Ag); secreted antigenic target 6 (ESAT-6) and culture filtrate
protein 10 (CFP-10) and phytohaemagglutinin (PHA) TB Ags
ratio to predict LTB infection. Among the immune compromised
and children above 2 years, this assay has sensitivity and
specificity >95%. Originally, the T-SPOT assay like all IGRAs
was not suitable for active TB diagnosis due to its inability to
differentiate active PTB from LTBI. Despite that shortcoming,
PHA IFNg levels were higher in active PTB group compared to
the no-TB group using ESAT-6 and CFP10 sfc ratio. Recently
a modification that uses the TBAg/PHA ratio in T-SPOT.TB
assay was analyzed for its ability to diagnose active PTB in a
PTB endemic setting. A study by Wang et al. (52) proposed
assesseing the ratio of ESAT-6 and CFP10 combined to PHA
for its predictive potential of active PTB disease. The results
showed good performance of the TB Ag/PHA with sensitivity
of 82.1% and specificity of 90.7% to distinguish active PTB
disease from LTBI. These results correlated with the results in a
larger multi center study offering sensitivity and specificity above
80% (53). Among the immune compromised, the sensitivity
reduced to 79.21 and specificity increased to 94.05 but was still
high enough for use among this population (54). In order to
improve sensitivity, modifications such as combining the TB
Ag/PHA ratio with tests like Xpert MTB/RIF and Prealbumin
have been made. When the Xpert MTB/RIF was used together
with the TB Ag/PHA ratio to distinguish active PTB from LTBI,
sensitivity improved to 88.05% and specificity of 96.26% (55)
while with prealbumin sensitivity was 91.67% and specificity was
90.48% (56).
Host Inflammatory Biomarkers Detectable in ex-vivo
Samples
Plasma and Serum Proinflammatory Cytokines,
Chemokines, and Growth Factors
Recent advances use multiplex ELISAs to analyze concentrations
of cytokines and chemokines for their ability to differentiate PTB
patients from latently infected subjects or healthy controls. When
serum and plasma levels of these markers were evaluated, pro-
inflammatory cytokines and chemokines like VEGF (57), IFNg,
IL-2, TNF alpha, IL-12p40, IL-10, GM-CSF, IL-1 beta, and IL-
6 were higher among active PTB patients compared to healthy
controls (58–60). Similarly, the samemarkers were higher among
active PTB children than their healthy counterparts. Importantly,
pediatric levels were lower than adult levels mainly because
the adult immune system is more developed compared to the
pediatric one (27). Active TB predictive biosignatures included;
“IL-6, MIP-1β, VEGF and saliva G-CSF and MIP-1α” (60) in a
Ugandan population. In a South African study, the predictive
biosignature among the HIV co-infected patients included IFN-
gamma, fibrinogen, IFN- alpha-2, MMP-2 (61), and IL-1RA;
ApoA-1, CFH, CRP, IFN-g, IP-10, SAA, and transthyretin (62).
Whole Blood Culture Cytokine and Chemokine
Production
Whole blood assays using recombinant proteins and Mtb
antigens such as ESAT-6, CFP-10, TB7.7 (63) as well as other
recombinant proteins (Rv2029c, Rv2032, Rv2389c) (64) have
been evaluated for the prediction of active TB disease. Attempts
to translate these promising markers into point of care tests have
been made with IP10 and CCL4 that have been incorporated
into a lateral flow platform (65). In a multisite African study,
unstimulated IFN-gamma, unstimulated TGF-α, and antigen-
specific levels of IL-1ra and MIP-1β diagnosed active TB
disease with a sensitivity and specificity >70% (48). Among
asymptomatic subjects, Apo-A1, ITAC-1, 1-309, MIG, MCP-2,
and NCAM-1 in the unstimulated sample (Nil) predicted active
TB with a sensitivity and specificity >70%, well as within the TB
antigen-stimulated sample, Apo-CIII, I-309, MIP-1α, and TNF-α
predicted active TB disease (49).
Despite the advances in this field, the challenge lies in the
fact that the most affected participant groups are not well-
covered by the testing methods available. These include pediatric
participants who cannot produce sputum and the HIV-infected
participants who have paucibacillary tuberculosis and usually
have negative sputum smear results.
Despite all the research, no new tests based on these bio-
signatures currently exist. However, there are studies in advanced
stages of development and clinical evaluation utilizing the
identified bio-signatures.
Mtb RNA for Active PTB Diagnosis
Mtb RNA has been used to detect presence of viable bacilli in
both sputum culture positive and negative participants. Among
the sputum culture negative participants with LTBI, viable but
non-culturable bacilli have been retrieved in previous studies
having both pulmonary and extra pulmonary TB (66). Attempts
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to diagnose to active PTB using Mtb RNA by analyzing 85B
mRNA, IS6110, 16S rRNA and 65 kDa heat shock protein have
been made using nucleic acid amplification techniques (67). The
IS6110 insertion sequence is being used for active PTB diagnosis
for its uniqueness among theMtb complex as a mobile promoter
(68) with a role in influencing growth of Mtb strains through
selective activation of monocytes (69). This has been translated
into a quick immune chemical assay with a TAT of 4 h (70).
The 16S rRNA gene has been studied for its diagnostic value in
Mtb complex due to the fact that its highly conserved among
Mycobacteria. In a South Korean study 16SrRNA provided a
sensitivity above 90% using PCR (71). It has also proven to
have great value in diagnosis of non-tuberculous mycobacterium
(NTMs) although its sensitivity is affected if samples are smear
negative (72). Messenger RNA for 85B is used for predicting
actively replicating bacilli an important aspect in detecting active
PTB disease as well as PTB treatment response (67, 73).
Blood Transcriptomic Signatures
Host control and eradication of Mtb are directed by the
regulation of transcription and host gene expression. These have
been highlighted as predictors of active PTB disease or treatment
outcomes (26). Tuberculosis gene studies indicated increased
expression of genes linked to apoptosis, immune-inflammatory
response, bacterial molecular pattern responses (74) regulatory
T-cell marker genes, and intracellular trafficking marker genes
(74). Alternate splicing of transcripts in blood samples is one of
the forms of transcription regulation given that it is also used
as an evasion mechanism by Mtb to escape immune response
(75). Blood gene signatures from paxgene blood samples have
proven important for predicting active TB disease. This includes
the expression of cytolytic and cell cycle genes which indicates
increased lymphocyte proliferation (76–78).
A blood transcriptional profiling study evaluating the
performance of 393 selected transcripts in a high TB endemic
setting compared to a low TB setting revealed that these
blood transcripts were indicative of successful treatment as they
would wane with treatment. Interferon-inducible transcripts
were identified and were over-expressed in purified blood
neutrophils and to lesser extent monocytes, but not CD4+ and
CD8+ T cells, from active TB patients, compared to healthy
controls (79). This signature identified by Berry et al. (79) has
been cited and utilized by other studies and has proven to be
differentiative of disease states as well as treatment response (80–
84). These genes include FCGR1B, CD64 (FCGR1A), LTF, GBP5,
and GZMA31. Transcriptomic signatures that are predictive of
active PTB in recent studies are highlighted in Figure 2. Many of
the markers keep coming up in the different studies and therefore
ought to be investigated for use in improved diagnosis of active
PTB (85).
Immune Metabolic Markers
Symptoms of pulmonary tuberculosis such as weight loss and
appetite loss are regulated bymetabolic alterations in the patients’
endocrine system. There is limited data about the use of immune
metabolic markers for their use in PTB diagnosis yet they play an
important role in the manifestation of TB signs and symptoms.
A study in Italy evaluated plasma endocrine markers like
cortisol, dehydroepiandrosterone (DHEA), Leptin, Ghrelin,
adiponectin, and pro-inflammatory markers like plasma CRP, IL-
1b, IL-6 for their ability to predict PTB among HIV negative
PTB patients, their household contacts, and healthy controls.
There were significant differences between levels of all the above
markers except for DHEA between PTB patients and either
household contacts or health controls (86).
Another study in Argentina assessed the use of immune
metabolic markers for predicting the efficacy of PTB treatment
response. Cortisol and DHEA were assessed at the initiation
of treatment, at months 2, 4, and 6 as well as 3 months after
treatment completion in this study. Cortisol levels increased
during treatment but return to normal by Month 3 post PTB
treatment well as DHEA levels were decreased among PTB
patients but returned to normal after the end of treatment
(87). When comparisons were made, saliva levels of DHEA
were reflective of blood levels but not for its sulfated derivative
(DHEA-S) (88). Saliva cortisol levels on the other hand were
lower than in blood (89, 90).
Tuberculosis Detection in Samples Other Than Blood
Globally, there is a push to develop assays that make use of
easily available sample types such as urine, saliva as well as the
need for assays that do not require overnight culture with the
aim of developing rapid and cheaper tests which are possible to
implement in resource-limited settings.
Urine lipoarabinomannan (LAM) has been an important
marker for TB among the HIV infected (17, 20, 91). Point of
care strips for LAM are available on the market for use among
the HIV infected. Importantly, the only approved antibody test
for TB is the Alere LAM. In the pipeline are the new formats of
LAM that are being investigated by FIND; SILVAMP TB LAM
(FujiLAM) (92, 93). A study on host markers in urine identified
a biosignature consisting of IL2-Ra, sIL2Ra, and MDC (CCL22)
that diagnosed active TB disease regardless of HIV status (94).
Saliva use for Mtb diagnosis was earlier highlighted (95)
and pro-inflammatory and inflammatory markers are in high
quantities in saliva (60, 96, 97). Studies comparing serum and
saliva levels demonstrated significant differences in the levels of
GM-CSF and VEGF in saliva compared to serum (60). Previous
studies showed that median levels of IL-17A, IL-23, and ECM-1
were significantly higher in the TB patients and were predictive of
treatment response (98). Levels of IL-1β and IL13 were higher in
saliva with IL-1β and VEGF appearing among the top markers
with diagnostic potential (60, 96) respectively. G-CSF, TNF-
α, and VEGF diagnosed active TB in a saliva model among
the Ugandan population (60). In a South African population,
a biosignature comprising CRP, ferritin, SAP, MCP-1, A2M,
fibrinogen, and TPA (97) as well as a signature comprising IL-
1β, IL-23, ECM-1, HCC1, and fibrinogen, diagnosed active TB
regardless of HIV status. When HIV was put into account, a
biosignature comprising, ENA-78, GDF-15, SAA, IL-12(p40), IL-
21, IL-13, granzyme A, and PAI-1 diagnosed active TB with a
sensitivity and specificity above 90% (98).
Other body fluids that have been used include bronchoalveolar
lavage (BAL), breath condensate, and pleural fluid. Breath
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FIGURE 2 | Blood transcriptomic markers predictive of active PTB. OAS, 2’-5’-Oligoadenylate Synthetase 1; IF, Interferon alpha-inducible protein 6; IFI, Interferon
Gamma Inducible Protein; IRF, Interferon Regulatory Factor; IFIH, Interferon-induced helicase C domain-containing protein; IFIT, Interferon Induced Protein With
Tetratricopeptide Repeats; IFITM, Interferon-induced transmembrane protein; GBP, guanylate-binding protein; STAT, signal transducer and activator of transcription;
TAP, Transporter associated with Antigen Processing; SOCS, Suppressor of cytokine signaling; CXCL, C-X-C Motif Chemokine Ligand; FCGR, Low-affinity
immunoglobulin gamma Fc region receptor; CD, Cluster of differentiation; LTF, Lactotransferrin; OSM, Oncostatin M; SERP-ING1, plasma protease C1 inhibitor; ICAM,
Intercellular Adhesion Molecule; CHRM, Cholinergic Receptor Muscarinic; AMPH, Amphiphysin; SNX, Sorting Nexin; PIGC, Phosphatidylinositol
N-acetylglucosaminyltransferase subunit C; TAS2R46, Taste 2 Receptor Member 46; HBD, Hemoglobin subunit delta; GLDC, Glycine Decarboxylase; ACOT,
Acyl-CoA thioesterase; S100P, S100 Calcium Binding Protein P; STYXL, Serine/Threonine/Tyrosine Interacting Protein; IL, interleukin; BCL, B-cell lymphoma; CASP,
cysteine-dependent aspartate-directed proteases; TGFB, transforming growth factor-beta; TGFBR, transforming growth factor-beta receptor; TNFRSFIB, tumor
necrosis factor II receptor; SEC, Selenocysteine; NCAM, Neural Cell Adhesion Molecule; CCR, C-C Motif Chemokine Receptor; PTPRCv, protein tyrosine
phosphatase receptor type C; GATA, Erythroid transcription factor. CTLA, Cytotoxic T-Lymphocyte Associated Protein; GNLY, Granulysin; TLR, Toll-like receptor; NLP,
Nucleoplasmin-like protein; TIMP, tissue inhibitor of metalloproteinases; AREG, Amphiregulin; RAB, G-protein; BPI, Bactericidal Permeability Increasing Protein;
TWIST, Twist-related protein; BLR, beta-lactam resistance protein; AIRE, Autoimmune regulator; MRC, Mannose Receptor C; Nod, nodulation; TAGAP, T-cell
activation RhoGTPase activating protein; SPP, Signal Peptide Peptidase.
condensate is still a virgin area of research for Mtb diagnosis
(20). Bronchoalveolar lavage (6) and pleural fluid are other
samples that have been utilized for the diagnosis of active PTB
disease because of their proximity to the site of infection. The
challenge is the invasive nature of acquiring the sample. Being
at the site of infection, BAL provides the true reflection of
what happens within the immune system when attacked by
Mtb (99).
Effect of Other Diseases on Pulmonary
Tuberculosis Disease Diagnosis
“Human immunodeficiency syndrome (HIV)” is a co-infection
whose presence fuels progression from latent tuberculosis to
active PTB disease. Because HIV compromises the immune
system, TST performance, as well as IGRA sensitivity, are highly
affected among HIV-infected persons. Lower CD4 counts are
associated with higher rates of indeterminate QuantiFERON
results. On the other hand, T-SPOT is less affected by HIV
immune suppression, as is the QuantiFERON and tuberculin
skin test. This is partly because the test utilizes an adequate
number of peripheral blood mononuclear cells despite overall
low CD4+ cell counts in whole blood (25). For this reason,
most studies utilize HIV-negative subjects to avoid confounding
results. This is problematic as those infected withHIV are atmore
risk of progression to active PTB disease compared to the healthy
subjects who most studies use. More investigations need to be
made in discovering more host-derived biomarker signatures to
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improve the diagnosis of active PTB in TB endemic areas as well
as among the presumptive TB cases that comprise a huge base of
TB transmission.
Diabetes has also been shown as another risk factor for
progression to active TB disease (100, 101). Another study
highlighted diabetes mellitus as a risk factor for tuberculosis
but recommended the classification of diabetes mellitus stages
for better association studies (102). Interestingly, while diabetes
mellitus is a risk factor for tuberculosis, tuberculosis too is a risk
factor for the progression of diabetes mellitus (103). An Indian
study showed that diabetes mellitus contributed to cavitation
during TB disease in either the right or the left lung lobes (104).
It is therefore important to assess these and other comorbidities




The diagnosis of PTB remains a challenge globally and enormous
research is going on around the globe to improve the currently
available PTB diagnostic methods. Immunodiagnostic markers
are still not yet approved for PTB diagnosis despite the fact that
more research is being made to identify biosignatures that can
be incorporated into POCs for PTB diagnosis. Recent advances
with the IGRA- T-SPOT assay where the TBAg/PHA ratio has
been cited to diagnose active PTB disease. Blood biosignatures
that predict active PTB have shown to be divergent in different
populations. However, a few have been used to develop POC tests
for identifying subjects with active PTB disease thus preventing
new infections in the population. Great progress has been made
with the nucleic acid amplification techniques for PTB diagnosis
and have been used to develop POCs such as the Xpert©
MTB/RIF assay. More research needs to be made to incorporate
otherMtb antigens that have proven to have diagnostic potential
such as 65 kDa heat shock protein, 85B mRNA, 16S rRNA and
IS6110. Host transcriptomic signatures are a promising avenue
for use as markers for PTB diagnosis although there’s still need
for more research regarding biosignature discovery and testing
among different populations. This is because, some markers
perform better in non PTB endemic areas yet when introduced in
endemic areas the results differ a lot. Besides HIV, other illnesses
like diabetis mellitus have shown to be risk factors for LTBI
progression to active PTB disease. In such cases, subjects who
present with these illness may need to be planned for prophylaxis
treatment once identified to be having LTBI. In the era of
COVID-19 pandemic which presents with symptom similar to
those of active PTB, it is important to rule out COVID-19 among
patients presenting at the TB clinics to avoid health workers and
clinic staff being infected.
Strengths and Limitations of the Study
Tremendous research in PTB diagnostics has been included
in the time frame for this review. This review does not
include studies for biomarkers for PTB treatment response, drug
resistance and relapse.
CONCLUSION AND RECOMMENDATIONS
In vitro stimulation is not completely representative of immune
response to tuberculosis given the doses of recombinant proteins
and lack of a regulatory mechanism. In this regard, only parts of
the pathogen are used which are quite different from the original
pathogen. Whether or not immune cells respond the same way
is still an area of great research. Further research ought to be
made with the T-SPOT assay in regard to the TBAg/PHA ratio
for active PTB diagnosis among PTB endemic areas in large
studies. Additionally, molecular diagnostics focusing on Mtb
RNA markers needs to be spearheaded for POC tests to improve
active PTB diagnosis. Subjects with comorbidities that are risk
factors for active PTB disease progression need to be intitated on
prophylaxis treatment to reduce on the number of new cases as
well as TB morbidity and mortality.
Translational research to test and incorporate all investigated
markers into point of care active pulmonary tuberculosis tests
is a field worth exploring given the available findings. This will
provide opportunities for research aimed at reducing active PTB
disease diagnostic challenges.
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